{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:01:35Z","timestamp":1777420895291,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC, FTC, and PPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search via MEDLINE through PubMed from August 2013 to January 2020 was performed using the key terms niraparib, PARP inhibitors, ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Completed and ongoing trials were identified through a review of the website trial registry https:\/\/www.clinicaltrials.gov .<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In a phase III, double-blind clinical trial, progression-free survival improved in patients treated with niraparib compared with placebo as maintenance treatment for patients with platinum-sensitive, recurrent OC: 21 versus 5.5 months in the germline breast cancer susceptibility gene ( gBRCA) cohort (hazard ratio [HR] = 0.27; 95% CI = 0.17 to 0.41; P &lt; 0.001) and 9.3 versus 3.9 months in the overall nongermline breast cancer susceptibility gene (non- gBRCA) cohort (HR = 0.45; 95% CI = 0.34 to 0.61; P &lt; 0.001). Adverse events included thrombocytopenia and anemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Poly (ADP-ribose) polymerase (PARP) inhibitors have gained a place in the therapeutic management of OC, FTC, and PPC because of their ability to suppress growth of homologous recombination deficiency\u2013positive tumors, including those with BRCA1\/2 mutations. Niraparib inhibits the DNA repair mechanism vital to the survival of cancer cells, poly-ADP ribose polymerase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PARP inhibitors can be used as a single agent for maintenance therapy for platinum-sensitive recurrent disease in patients with partial or complete response following 2 or more rounds of platinum-based therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020912749","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T03:28:25Z","timestamp":1584329305000},"page":"1010-1015","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"],"prefix":"10.1177","volume":"54","author":[{"given":"Lloreta","family":"Kerliu","sequence":"first","affiliation":[{"name":"Sanofi-Genzyme, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Myruski","sequence":"additional","affiliation":[{"name":"Sanofi-Genzyme, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afeefa","family":"Bhatti","sequence":"additional","affiliation":[{"name":"Sanofi-Genzyme, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyal","family":"Soni","sequence":"additional","affiliation":[{"name":"Sanofi-Genzyme, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulius","family":"Petrosius","sequence":"additional","affiliation":[{"name":"Sanofi-Genzyme, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen C.","family":"Pervanas","sequence":"additional","affiliation":[{"name":"MCPHS University Worcester\/Manchester, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-1875","authenticated-orcid":false,"given":"Evan R.","family":"Horton","sequence":"additional","affiliation":[{"name":"MCPHS University Worcester\/Manchester, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"bibr1-1060028020912749","unstructured":"National Cancer Institute, PDQ\u00ae Adult Treatment Editorial Board. PDQ ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ\u00ae)\u2013Health Professional Version. https:\/\/www.cancer.gov\/types\/ovarian\/hp\/ovarian-epithelial-treatment-pdq#section_7.42. Accessed June 26, 2019."},{"key":"bibr2-1060028020912749","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: ovarian cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed June 27, 2019."},{"key":"bibr3-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.12.002"},{"key":"bibr4-1060028020912749","unstructured":"Lynparza [package insert]. Wilmington, DE: AstraZeneca; 2018."},{"key":"bibr5-1060028020912749","unstructured":"Zejula [package insert]. Waltham, MA: Tesaro; 2019."},{"key":"bibr6-1060028020912749","unstructured":"Rubraca [package insert]. Boulder, CO: Clovis Oncology Inc; 2018."},{"key":"bibr7-1060028020912749","unstructured":"Talazoparib [package insert]. New York, NY: Pfizer; 2019."},{"key":"bibr8-1060028020912749","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2016.65667"},{"key":"bibr9-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1021\/jm5018237"},{"key":"bibr10-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70240-7"},{"key":"bibr11-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472"},{"key":"bibr12-1060028020912749","unstructured":"Center for Drug Evaluation and Research. PMR\/PMC development template: Zejula (niraparib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208447Orig1s000OtherR.pdf. Accessed February 26, 2020."},{"key":"bibr13-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e16531"},{"key":"bibr14-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"bibr15-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1297423"},{"key":"bibr16-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"},{"key":"bibr17-1060028020912749","unstructured":"National Comprehensive Cancer Network. Ovarian cancer (version 2.2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. Accessed February 28, 2019."},{"key":"bibr18-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"bibr19-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"bibr20-1060028020912749","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.5533"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020912749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020912749","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020912749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:29Z","timestamp":1777374929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020912749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1177\/1060028020912749"],"URL":"https:\/\/doi.org\/10.1177\/1060028020912749","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]}}}